King Pharmaceuticals Gets Positive Initial Results On New Drug
By Gary Gray
Reporter / Bristol Herald Courier
Published: June 22, 2008
BRISTOL, Tenn. – King Pharmaceuticals and Acura Pharmaceuticals Inc. announced last week positive results from the study of a new medication aimed at deterring prescription drug abuse.
King, and Palatine, Ill.- based Acura, plan to submit a new drug application to the U.S. Food and Drug Administration for Acurox tablets by the end of this year.
The joint effort also includes the possible FDA approval of another pain-killing drug. Both drugs were developed by using Acura’s patented Aversion Technology – the name given for the methods used to create the deterring properties.
If approved, King would market and sell the two new drugs.
In December 2007, the two companies signed an agreement to jointly develop a new opioid analgesic for pain relief. An opioid is a chemical substance that has a morphine-like action in the body.
“About 50 million Americans are dealing with chronic pain that lasts weeks, months, perhaps a lifetime,” said James Green, King’s vice president of corporate affairs. “The prescription medications available are being misused, and that’s having an effect on physicians’ ability to treat pain.” More…